References
- Finsterer J. Congenital myasthenic syndromes. Orphanet J Rare Dis. 2019;14(1):57. doi: 10.1186/s13023-019-1025-5.
- McMacken G, Abicht A, Evangelista T, et al. The increasing genetic and phenotypical diversity of congenital myasthenic syndromes. Neuropediatrics. 2017;48(4):294–308. doi: 10.1055/s-0037-1602832.
- Souza PV, Batistella GN, Lino VC, et al. Clinical and genetic basis of congenital myasthenic syndromes. Arq Neuropsiquiatr. 2016;74(9):750–760. doi: 10.1590/0004-282X20160106.
- Shieh PB, Oh SJ. Congenital myasthenic syndromes. Neurol Clin. 2018;36(2):367–378. doi: 10.1016/j.ncl.2018.01.007.
- Engel AG, Shen XM, Selcen D, et al. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(4):420–434. doi: 10.1016/S1474-4422(14)70201-7.
- Huang K, Luo YB, Bi FF, et al. Pharmacological strategy for congenital myasthenic syndrome with CHRNE mutations: a meta-analysis of case reports. Curr Neuropharmacol. 2021;19(5):718–729. doi: 10.2174/1570159X18666200729092332.
- Parr JR, Andrew MJ, Finnis M, et al. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child. 2014;99(6):539–542. doi: 10.1136/archdischild-2013-304788.
- Verma S, Mazell SN, Shah DA. Amifampridine phosphate in congenital myasthenic syndrome. Muscle Nerve. 2016;54(4):809–810. doi: 10.1002/mus.25230.
- Iyadurai SJP. Congenital myasthenic syndromes. Neurol Clin. 2020;38(3):541–552. doi: 10.1016/j.ncl.2020.03.004.
- Abicht A, Müller JS, Lochmüller H. Congenital myasthenic syndromes overview. University of Washington: seattle;. 2021.
- Jónsson H, Sulem P, Kehr B, et al. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 2017;549(7673):519–522. doi: 10.1038/nature24018.